Stockscreener 앱 받기
2.46
4.65%
-0.12
시간 외 거래:
2.46
Alaunos Therapeutics Inc 주식(TCRT)의 최신 뉴스
Alaunos Therapeutics Secures $25M Equity Purchase Deal - MSN
Ziopharm: Q1 Earnings Snapshot - CT Insider
Alaunos Therapeutics (NASDAQ:TCRT) Trading Down 2.4% – Time to Sell? - Defense World
PMGC Capital announces filing to report 5.09% stake in Alaunos Therapeutics - TipRanks
PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. - GlobeNewswire
PMGC Capital Takes 5.09% Stake in Alaunos Therapeutics, Eyes Strategic Changes Including Fintech Expansion - Stock Titan
Alaunos Therapeutics (NASDAQ:TCRT) Trading Up 2.5% – Time to Buy? - Defense World
Alaunos Therapeutics announces board member resignation - Investing.com Australia
Alaunos Therapeutics announces board member resignation By Investing.com - Investing.com Canada
Form 8-KCurrent report - ADVFN
Alaunos Therapeutics Board Opts for Equity Compensation - TipRanks
Alaunos Therapeutics announces private placement of preferred stock By Investing.com - Investing.com Canada
Alaunos Therapeutics announces private placement of preferred stock - Investing.com
Alaunos Therapeutics And 2 Other Promising Penny Stocks To Watch - simplywall.st
Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Short Interest Down 12.5% in March - Defense World
11 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday SessionAllakos (NASDAQ:ALLK), Alumis (NASDAQ:ALMS) - Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Alaunos Therapeutics Inc. (TCRT) reports earnings - Quartz
Alaunos Therapeutics (NASDAQ:TCRT) Shares Down 6.5% – Here’s What Happened - Defense World
Lantheus acquires radiopharma CDMO Evergreen for up to $1bn - Pharmaceutical Technology
Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Up 4% – Should You Buy? - Defense World
Update: Johnson & Johnson acquires Intra-Cellular Therapies - Pharmaceutical Technology
Light Horse emerges with $62m and Novartis partnership worth up to $1bn - Pharmaceutical Technology
Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Down 0.5% – Time to Sell? - Defense World
TCRT stock touches 52-week low at $1.92 amid market challenges - Investing.com
Novartis acquires Kate Therapeutics to advance gene therapies - Pharmaceutical Technology
Ziopharm: Q3 Earnings Snapshot - San Francisco Chronicle
Alaunos Therapeutics Inc (TCRT) Quarterly 10-Q Report - qz.com
TCRT Stock Touches 52-Week Low at $1.96 Amid Market Challenges - Investing.com
After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen - Fierce Biotech
Precigen Terminates License Agreement With Alaunos Therapeutics - MarketWatch
Genentech buys Regor’s CDK inhibitors in $850m deal - Clinical Trials Arena
VION Biosciences acquires Echelon Biosciences - Pharmaceutical Technology
TCRT stock touches 52-week low at $2.28 amid market challenges - Investing.com India
Eli Lilly inaugurates R&D facility in Boston, US - Pharmaceutical Technology
Alaunos Therapeutics announces 1-for-10 reverse stock split - Investing.com
Avenzo Therapeutics secures $150m to bolster oncology pipeline - Pharmaceutical Technology
Gilead concludes acquisition of CymaBay Therapeutics for $4.3bn - Pharmaceutical Technology
Alaunos Therapeutics Announces 1-for-15 Reverse Stock Split - TipRanks
Kyowa Kirin acquires Orchard Therapeutics for $477.6m - Pharmaceutical Technology
NAYA buys gene therapy company Florida Biotech for $20m - Clinical Trials Arena
Genentech signs nanoparticle deal worth up to $644m with GenEdit - Pharmaceutical Technology
BridGene and Galapagos partner for oncology drugs discovery - Pharmaceutical Technology
Novartis allies with Voyager to develop gene therapies in $1.3bn deal - Pharmaceutical Technology
Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today? - MSN
ELABPMGC Holdings Latest Stock News & Market Updates - Stock Titan
Syncona to buy biotechnology company Freeline Therapeutics - Pharmaceutical Technology
Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives - Yahoo Finance
Ascidian Therapeutics raises $40m to advance drug development - Pharmaceutical Technology
AstraZeneca and Cellectis partner to advance cell and gene therapies - Pharmaceutical Technology
How gene therapies can transform sickle cell disease treatment - Pharmaceutical Technology
StockWatch: Illumina Results Leave Investors, Analysts Anxious - Genetic Engineering and Biotechnology News
Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65% - Nasdaq
Houston biotech winds down sole clinical-stage trial, cuts 60% of staff - Fierce Biotech
Houston BioTech Donation Enriches UH Program - University of Houston
15 Biotech Stocks Wall Street Analysts Say Are Too Cheap - Barron's
Hopewell Therapeutics raises funds for genomic medicines development - Pharmaceutical Technology
1.89%
3.74%
자본화:
|
볼륨(24시간):